VOLTAS launches in-house ETO sterilization with faster validation

VOLTAS says its ISO 13485-compliant facility now offers in-house ethylene oxide sterilization for medical device makers, cutting validation timelines by 50% versus outsourced workflows at no extra cost. The move keeps cleanroom assembly, packaging, validation and documentation under one roof for faster handoffs and fewer vendors.

Why it matters: - Medical device makers can now keep sterilization inside the same facility as assembly and packaging, reducing handoffs and vendor coordination. - VOLTAS says the in-house model cuts sterilization validation time by 50% compared with traditional outsourced processes, without adding cost. - The service is aimed at single-use devices that cannot withstand heat or radiation sterilization.

What happened: - VOLTAS announced in-house ethylene oxide, or ETO, sterilization services for medical device companies. - The company says the service is available now for startups and established manufacturers. - The work is handled at VOLTAS' ISO 13485-compliant facility in Cottage Grove, Minnesota.

The details: - VOLTAS supports ETO sterilization runs from small routine batches to full pallet sterilization. - The offering covers development-stage builds and ongoing commercial volumes. - The service list includes in-house ETO sterilization, sterile barrier packaging and labeling, full sterilization validation, cycle development, cleanroom assembly through sterilization, and regulatory documentation support. - Devices can move from cleanroom assembly through a validated ETO cycle without leaving the building. - VOLTAS says the setup provides full traceability through the process. - The company says manufacturers no longer need to wait on an external lab's schedule or manage separate validation and documentation relationships.

Between the lines: - The announcement fits VOLTAS' broader model of combining engineering, quality, manufacturing, regulatory and commercialization services under one roof. - Keeping sterilization in-house may also reduce the risk of delays that can happen when product is transferred between separate vendors. - VOLTAS positions the offer as useful for hardest-to-sterilize studies as well as routine terminal sterilization.

What's next: - VOLTAS says the service will support terminal sterilization, validation work and ongoing commercial production. - Device makers can use the in-house service while keeping the documentation needed for submissions and audits on track. - More information is available at voltas.io and on the company's LinkedIn page.

The bottom line: - VOLTAS is betting that faster validation, fewer handoffs and one integrated team will make ETO sterilization easier for medical device developers.